MedPage Today: Triple Combo Tx Durable for T2D

September 1, 2016

Starting newly-diagnosed diabetes patients on the triple combination of metformin/pioglitazone/exenatide upfront provided better glucose control with less hypoglycemia than a standard sequential regimen, 3-year follow-up from the EDICT trial showed. Read the full story at MedPage Today


UTSA Today: UTSA alumna’s medical device receives UT System investment

September 1, 2016

The UT Horizon Fund recently invested $150,000 to fund Cardiovate, a San Antonio-based startup that is using technology from two University of Texas System institutions to commercialize a medical device to treat vascular diseases by repairing blood vessels. Read the full story at UTSA Today